Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
Funding Amount
Up to $300,000
Deadline
November 18, 2027
386 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- City & township governments
- Public & Indian housing authorities
- School districts
- Small businesses
- Special district governments
- Public colleges & universities
- Nonprofits (501(c)(3))
- County governments
Geography
- Non-domestic (non-U.S.) components of U.S.
Not eligible / not funded
- Not eligible: Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
- Not eligible: Organizations are not eligible to apply.
Overview
This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-DA-26-034
- Total Funding: $300,000
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Focus Areas & Funding Uses
Fields of Work
- Addiction recovery
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
October 30, 2026
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health
Amount
$2,000,000 total
Deadline
October 30, 2026
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
Amount
$3 – $500K
Deadline
October 30, 2026
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 30, 2026
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Ready to apply for Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed). Now let's win it.